Core Viewpoint - China National Nuclear Corporation's subsidiary, Shenzhen Zhongke Haidewei Biotechnology Co., Ltd., has received acceptance for its application of "Injectable Boron [10B] Phenylalanine" from the National Medical Products Administration, marking a significant step in the development of innovative cancer treatments in China [1] Group 1 - The injectable boron [10B] phenylalanine is designed for patients with tumors that are resistant to radiotherapy and chemotherapy, including recurrent, refractory, infiltrative, advanced, and locally metastatic cancers, showcasing significant clinical advantages [1] - The treatment requires only 1-2 sessions, has low toxicity and side effects, and integrates diagnosis and treatment, representing a breakthrough in modern precision oncology [1] - The submission of the IND application for BNCT boron drug signifies a breakthrough in the collaborative research and development of domestic BNCT technology, entering a new phase of clinical transformation [1] Group 2 - This development aligns with the "Healthy China" strategy, injecting new momentum from nuclear technology into precision cancer treatment and contributing a "Chinese solution" to global cancer therapy [1]
中国同辐附属公司中核海得威BNCT硼药提交IND申请